Who are ACTH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crenessity, Open label H.P. Acthar Gel, Purified Cortophin Gel, 40 U, H.P. ACTHAR SUBCUTANEOUS GEL INJECTION, Purified Cortophin Gel 80 U, H.P. Acthar Gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acth.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ACTH — Competitive Intelligence Brief

ACTH (ACTH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticotropin; peptide hormone. Area: Endocrinology; Immunology; Rheumatology.

marketed Corticotropin; peptide hormone Melanocortin-2 receptor (MC2R) Endocrinology; Immunology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

ACTH (ACTH) — Providence Health & Services. ACTH (adrenocorticotropic hormone) stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACTH TARGET	ACTH	Providence Health & Services	marketed	Corticotropin; peptide hormone	Melanocortin-2 receptor (MC2R)
Crenessity	CRINECERFONT	Neurocrine	marketed	Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]		2024-01-01
Open label H.P. Acthar Gel	Open label H.P. Acthar Gel	Fiechtner, Justus J., M.D., P.C.	marketed	Corticotropin (ACTH analog)	Melanocortin-2 receptor (MC2R)
Purified Cortophin Gel, 40 U	Purified Cortophin Gel, 40 U	Massachusetts General Hospital	marketed	ACTH analog / corticotropin	Melanocortin-2 receptor (MC2R)
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION	H.P. ACTHAR SUBCUTANEOUS GEL INJECTION	Tampa Bay Uveitis Center, LLC	marketed	Corticotropin (ACTH) analog	Melanocortin receptors (primarily MC2R on adrenal cortex; also MC1R, MC3R, MC4R, MC5R on immune cells)
Purified Cortophin Gel 80 U	Purified Cortophin Gel 80 U	Massachusetts General Hospital	marketed	ACTH analog / corticotropin	Melanocortin-2 receptor (MC2R)
H.P. Acthar Gel	H.P. Acthar Gel	Fiechtner, Justus J., M.D., P.C.	marketed	Corticotropin (ACTH analog)	Melanocortin-2 receptor (MC2R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticotropin; peptide hormone class)

Providence Health & Services · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACTH — Competitive Intelligence Brief. https://druglandscape.com/ci/acth. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab